Send to

Choose Destination
Sci Rep. 2016 Dec 6;6:38273. doi: 10.1038/srep38273.

Identification of KIAA1199 as a Biomarker for Pancreatic Intraepithelial Neoplasia.

Author information

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Department of Molecular Biology, Pusan National University, Busan, Republic of Korea.
Department of Pathology, The University of Texas Medical School, Houston, TX, 77030, USA.
Department of Internal Medicine, Gyeong-Sang National University Hospital, Jinju, Republic of Korea.
Graduate School of Biomedical Sciences at Houston, Houston, TX, 77030, USA.
Program in Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.


Pancreatic cancer is one of the most aggressive cancers and has an extremely poor prognosis. Despite recent progress in both basic and clinical research, most pancreatic cancers are detected at an incurable stage owing to the absence of disease-specific symptoms. Thus, developing novel approaches for detecting pancreatic cancer at an early stage is imperative. Our in silico and immunohistochemical analyses showed that KIAA1199 is specifically expressed in human pancreatic cancer cells and pancreatic intraepithelial neoplasia, the early lesion of pancreatic cancer, in a genetically engineered mouse model and in human patient samples. We also detected secreted KIAA1199 protein in blood samples obtained from pancreatic cancer mouse models, but not in normal mice. Furthermore, we found that assessing KIAA1199 autoantibody increased the sensitivity of detecting pancreatic cancer. These results indicate the potential benefits of using KIAA1199 as a biomarker for early-stage pancreatic cancer.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center